The innate and adaptive immune systems represent our two arms of defense against infection and cancer. Natural killer (NK) cells are a central component of innate immunity, recognizing infected cells, stressed cells and tumor cells via specific nonpolymorphic receptors. As the critical presenters of antigen to naive T cells, dendritic cells (DCs) are the critical initiators of adaptive immunity. Coordination of immune responses requires efficient communication between innate and adaptive immunity. Recently, we discovered a unique hybrid cell type that expresses both NK molecules (activating and inhibitory) and DC molecules, termed NKDC. Murine NKDCs are related to, but distinct from classic plasmacytoid DC (PDCs). Upon activation with CpG oligonucleotide ligands for toll-like receptor (TLR)-9, NKDC become transiently activated to kill target cells. The killing is, at least in part, NKG2D-dependent. Their NK activity subsequently diminishes associated with loss of NKG2D and its adaptor, DAP-12. As NK activity is lost, DC-like antigen presenting activity is gained, associated with upregulation of surface MHC class II and costimulatory molecules. In vivo, splenic NKDCs preferentially display NK activity while lymph node NKDCs preferentially display ARC activity. By virtue of their capacity to mediate natural killing activity, followed by antigen presenting activity, NKDC may represent a direct link between innate and adaptive immunity. We propose to characterize the development and functions of this cell type in detail. The following specific aims will be pursued.
Specific Aim #1 : Define the developmental biology of NKDC relative to NK cells and classic DC.
Specific Aim #2 : Define the activation, recognition and effector molecules involved in NKDC killing.
Specific Aim #3 : Define the capacity of NKDC to process and present antigens to T cells.
Specific Aim #4 : Define the role of NKDC in response to tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI064826-04
Application #
7540963
Study Section
Special Emphasis Panel (ZRG1-IHD (01))
Program Officer
Gondre-Lewis, Timothy A
Project Start
2006-01-01
Project End
2010-12-31
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
4
Fiscal Year
2009
Total Cost
$390,546
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Abel, Alex M; Schuldt, Kristina M; Rajasekaran, Kamalakannan et al. (2015) IQGAP1: insights into the function of a molecular puppeteer. Mol Immunol 65:336-49
Guo, Hailong; Kumar, Pawan; Moran, Thomas M et al. (2009) The functional impairment of natural killer cells during influenza virus infection. Immunol Cell Biol 87:579-89
Pletneva, Maria; Fan, Hongni; Park, Jang-June et al. (2009) IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res 69:6607-14
Reinbold, Corbett J A; Malarkannan, Subramaniam (2008) Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues. Mol Immunol 45:1318-26
Regunathan, Jeyarani; Chen, Yuhong; Kutlesa, Snjezana et al. (2006) Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells. J Immunol 177:5365-76